Skip to main navigation Skip to search Skip to main content

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

  • GEMO Study Collaborators
  • , GC-HBOC Study Collaborators
  • , EMBRACE Collaborators
  • , OPAL Study Group
  • , AOCS Group
  • , KConFab Investigators
  • , HEBON Investigators
  • , The OCAC Consortium
  • , The CIMBA Consortium
  • Laboratoire de Genetique et Biologie des Cancers
  • Institut Curie
  • Mines ParisTech
  • University of Cologne
  • University of Cambridge
  • University of Cambridge
  • Population Health Department
  • Queensland Institute of Medical Research
  • Peter Maccallum Cancer Centre
  • Centre for Cancer Research
  • The University of Sydney
  • Netherlands Cancer Institute
  • Department of Gynecologic Oncology
  • Duke University
  • Cedars-Sinai Medical Center
  • Institute of Cancer Research
  • Radboud University Nijmegen
  • Netherlands Comprehensive Cancer Organisation
  • Antoni van Leeuwenhoek Hospital
  • IRCCS Istituto Oncologico Veneto - Padova
  • University of Toronto
  • University of California at Irvine
  • N.N. Alexandrov Research Institute of Oncology and Medical Radiology
  • ‘Agii Anargiri’ Cancer Hospital
  • University of Texas MD Anderson Cancer Center
  • Lund University
  • Vall d'Hebron Institute of Oncology
  • Vall d’Hebron University Hospital
  • Rutgers - The State University of New Jersey, New Brunswick
  • Landspitali University Hospital
  • University of Iceland
  • Friedrich-Alexander University Erlangen-Nürnberg
  • Vanderbilt University
  • Centro de Investigación en Red de Enfermedades Raras (CIBERER)
  • Centro Nacional de Investigaciones Oncológicas
  • Russian Academy of Sciences
  • Princess Margaret Cancer Centre
  • University of Bergen
  • National Institutes of Health
  • Hannover Medical School
  • IRCCS Istituto Europeo di Oncologia - Milano
  • Cancer Research UK Cambridge Institute
  • Maria Sklodowska-Curie Institute of Oncology
  • University of Helsinki
  • University of Utah
  • Pisa University Hospital
  • University of Melbourne
  • Roswell Park Cancer Institute
  • Ohio State University
  • German Cancer Research Center
  • University of Hamburg
  • Tianjin Medical University
  • Westmead Hospital
  • Columbia University
  • Ghent University
  • University of New Mexico
  • Alberta Health Services
  • Mayo Clinic Rochester, MN
  • Fox Chase Cancer Center
  • Memorial Sloan-Kettering Cancer Center
  • Cambridge

Research output: Contribution to journalArticlepeer-review

Abstract

Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, “select and shrink for summary statistics” (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28–1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08–1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21–1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29–1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35–1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.

Original languageEnglish
Pages (from-to)349-362
Number of pages14
JournalEuropean Journal of Human Genetics
Volume30
Issue number3
DOIs
StatePublished - Mar 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Polygenic risk modeling for prediction of epithelial ovarian cancer risk'. Together they form a unique fingerprint.

Cite this